Hansoh Pharmaceutical Group Company Limited (FRA:3KY)

Germany flag Germany · Delayed Price · Currency is EUR
2.840
-0.220 (-7.19%)
Last updated: May 28, 2025
44.16%
Market Cap 18.10B
Revenue (ttm) 1.62B
Net Income (ttm) 578.53M
Shares Out n/a
EPS (ttm) 0.10
PE Ratio 31.28
Forward PE 32.73
Dividend 0.04 (1.41%)
Ex-Dividend Date Sep 20, 2024
Volume n/a
Average Volume 4,201
Open 2.860
Previous Close 3.060
Day's Range 2.840 - 2.860
52-Week Range 1.800 - 3.060
Beta n/a
RSI 60.99
Earnings Date May 27, 2025

About FRA:3KY

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei... [Read more]

Industry Pharmaceutical Preparations
Founded 1995
Employees 8,989
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3KY
Full Company Profile

Financial Performance

In 2024, FRA:3KY's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.